Dr. Dave S Atteberry, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 6101 Summitview Ave Ste 200, Yakima, WA 98908 Phone: 509-902-8857 Fax: 509-902-8855 |
Dr. Eduardo Meirelles, M.D., PH.D Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 1110 N. 35th Ave, Yakima, WA 98902 Phone: 509-834-7050 Fax: 509-834-7051 |
Leslie R Bornfleth, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 111 S 11th Ave, Suite 321, Yakima, WA 98902 Phone: 509-248-3954 Fax: 509-248-3955 |
Voderbet C Kamath, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 307 S 12th Ave, Ste 19, Yakima, WA 98902 Phone: 509-469-1446 Fax: 509-469-1905 |
News Archive
A new study highlights that children suffering from inflammatory bowel disease (IBD) are not meeting the daily recommended intake of calcium and vitamin D. The research, conducted at Great Ormond Street Hospital for Children in London, identified that only 26.6% and 21.3% of paediatric IBD patients were achieving the current recommended intake for calcium and vitamin D respectively.
A new development in engineering chimeric antigen receptor (CAR) T cells, called affinity tuning, can make the CAR T cells spare normal cells and better recognize and attack cancer cells, which may help lower the toxicity associated with this type of immunotherapy when used against solid tumors, according to a preclinical study.
A new study published in the journal PLOS ONE reports a model that is based on air travel, using the number of passengers flowing between international airports to predict how many of the air travellers arriving at any of these airports will have dengue, in a month.
Qualcomm Life, Inc., a subsidiary of Qualcomm Incorporated, and AMC Health, a privately held provider of 'real-time' patient management solutions, today announced a collaborative effort to accelerate the transformation of chronic care and population health management by significantly enhancing connectivity and care coordination for at-risk patients, specifically those with heart failure, hypertension, diabetes, asthma or COPD, in a cost-effective manner.
Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company today announced results of the PREVAIL U.S. study (Pitavastatin compaREd with praVAstatin In Lowering LDL-C in the U.S.) which evaluated the efficacy of LIVALO (pitavastatin) 4 mg compared with pravastatin 40 mg in reducing low-density lipoprotein cholesterol (LDL-C), the primary endpoint, as well as effects on other lipid parameters and lipoprotein particles in adult patients with primary hyperlipidemia or mixed dyslipidemia.
› Verified 7 days ago